Xeris Biopharma Holdings, Inc. (XERS) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-03-02
How it makes money
Recorlev revenue increased by 75.0 million in 2025, serving Cushing’s syndrome patients in the United States for whom the approximately two-thirds surgery cure rate failed.
Net revenue growth is primarily driven by Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia. While surgery cures approximately two-thirds of patients, the remaining balance requires pharmacologic treatment.
The company also generates revenue from Gvoke, a liquid-stable glucagon rescue product for diabetes, and Keveyis, the first approved therapy for primary periodic paralysis. Profitability relies on increasing volume through patient demand and managing the net pricing offsets from payor rebates and patient assistance programs.
What protects it: the moat
Recorlev holds orphan drug exclusivity until December 30, 2028, while 175 global patents protect formulations that expire as late as 2036.
The company protects its earnings through a combination of orphan drug exclusivity and a broad patent estate. Recorlev benefits from exclusive status through 2028 and additional patents through 2040.
Gvoke is protected by composition of matter patents for its non-aqueous liquid formulation until 2036. These proprietary XeriSol and XeriJect technologies prevent rivals from easily replicating ready-to-use, room-temperature stable injectables that do not require reconstitution.
What growth costs
Selling and general expenses increased by 18.9 million in 2025 as the company achieved 0.6 million net income and continued its Recorlev expansion.
The company relies on a dedicated commercial organization and specialty pharmacies to identify and retain patients in rare disease markets. In 2025, it expanded its Recorlev sales force, contributing to a significant increase in personnel-related expenses.
Research and development spending is focused on XP-8121, a Phase 3-ready subcutaneous levothyroxine candidate. The business model depends on third-party contract manufacturing organizations (CMOs) for all production, assembly, and distribution, avoiding internal capital expenditures for manufacturing infrastructure.
What could damage it
Default on the 200.0 million term loans would allow lenders to seize assets including intellectual property, threatening the company after its 671.3 million deficit.
The company's financial stability is tied to its Amended and Restated Credit Agreement with Hayfin Services LLP. This 200.0 million facility is secured by substantially all property, including its vital patent portfolio.
A default, which could be triggered by failing to meet restrictive covenants or a fundamental change in ownership, would permit lenders to accelerate debt repayment and seize the core technologies that underpin its entire product line and future pipeline.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.